A citation-based method for searching scientific literature




Hiddo J L Heerspink, Bruce A Perkins, David H Fitchett, Mansoor Husain, David Z I Cherney. Circulation 2016
Times Cited: 542




List of shared articles



Times cited

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Diabetes 2021
3

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
Emily Brown, John P H Wilding, Uazman Alam, Thomas M Barber, Janaka Karalliedde, Daniel J Cuthbertson. Ann Med 2021
2

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl,[...]. Am J Kidney Dis 2021
11

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study.
Moa Lugner, Naveed Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzén, Ann-Marie Svensson, Björn Eliasson. Cardiovasc Diabetol 2021
3

Cardiorenal Protection in Diabetic Kidney Disease.
Jason F Lee, Ecaterina Berzan, Vikas S Sridhar, Ayodele Odutayo, David Z I Cherney. Endocrinol Metab (Seoul) 2021
2

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
Charlotte C van Ruiten, Annemarie B van der Aart-van der Beek, Richard G IJzerman, Max Nieuwdorp, Klaas Hoogenberg, Daniël H van Raalte, Hiddo J L Heerspink. Diabetes Obes Metab 2021
1

From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes.
Ofri Mosenzon, Stefano Del Prato, Meir Schechter, Lawrence A Leiter, Antonio Ceriello, Ralph A DeFronzo, Itamar Raz. Cardiovasc Diabetol 2021
3

Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function.
Teresa Salvatore, Alfredo Caturano, Raffaele Galiero, Anna Di Martino, Gaetana Albanese, Erica Vetrano, Celestino Sardu, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso. Biomedicines 2021
0

Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
Ele Ferrannini, Simona Baldi, Juan P Frías, Cristian Guja, Elise Hardy, Enrico Repetto, Serge A Jabbour, Ralph A DeFronzo. Diabetes Obes Metab 2020
2

The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.
Yuliya Lytvyn, Petter Bjornstad, Daniel H van Raalte, Hiddo L Heerspink, David Z I Cherney. Endocr Rev 2020
25

Renal physiology of glucose handling and therapeutic implications.
David Z Cherney, Mehmet Kanbay, Julie A Lovshin. Nephrol Dial Transplant 2020
18

Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus.
Steven B Heymsfield, Annaswamy Raji, Silvina Gallo, Jie Liu, Annpey Pong, Hakima Hannachi, Steven G Terra. Obesity (Silver Spring) 2020
3

Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Chrysanthi Mantsiou, Thomas Karagiannis, Panagiota Kakotrichi, Konstantinos Malandris, Ioannis Avgerinos, Aris Liakos, Apostolos Tsapas, Eleni Bekiari. Diabetes Obes Metab 2020
7


Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection.
Vikas S Sridhar, Lisa Dubrofsky, Jacinthe Boulet, David Z Cherney. J Bras Nefrol 2020
2

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini. Cardiovasc Diabetol 2020
9

New pharmacological strategies for protecting kidney function in type 2 diabetes.
Marcel H A Muskiet, David C Wheeler, Hiddo J L Heerspink. Lancet Diabetes Endocrinol 2019
29